KCM
NTLA icon

Kennedy Capital Management’s Intellia Therapeutics NTLA Stock Holding History

Kennedy Capital Management’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$513K Buy
30,292
+868
+3% +$12.1K 0.01% 521
2026
Q1 		$377K Buy
29,424
+2,415
+9% +$30.8K 0.01% 520
2025
Q4 		$243K Buy
27,009
+495
+2% +$6.81K 0.01% 526
2025
Q3 		$458K Buy
26,514
+13,005
+96% +$160K 0.01% 535
2025
Q2 		$127K Buy
13,509
+496
+4% +$4.07K ﹤0.01% 578
2025
Q1 		$92.5K Buy
13,013
+166
+1% +$1.68K ﹤0.01% 640
2024
Q4 		$150K Buy
12,847
+2,381
+23% +$37.2K ﹤0.01% 665
2024
Q3 		$215K Buy
+10,466
New +$241K ﹤0.01% 673
2022
Q2 		– Sell
-3,348
Closed -$243K – 626
2022
Q1 		$243K Buy
3,348
+905
+37% +$76.7K 0.01% 580
2021
Q4 		$289K Sell
2,443
-209
-8% -$26.2K 0.01% 593
2021
Q3 		$356K Sell
2,652
-55
-2% -$8.33K 0.01% 603
2021
Q2 		$438K Buy
+2,707
New +$211K 0.01% 592

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Kennedy Capital Management's NTLA Position: Q2 2026 in Review

Kennedy Capital Management increased its Intellia Therapeutics (NTLA) stake by 2.9% in Q2 2026, buying an estimated $12.1K and bringing the position to 30,292 shares worth $513K. The position accounts for 0.01% of the portfolio, ranked #521.

Kennedy Capital Management first reported a position in NTLA in Q2 2021 and has held it in 12 quarters since. 328 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • Kennedy Capital Management held 30,292 shares of Intellia Therapeutics worth $513K as of Q2 2026.
  • Kennedy Capital Management bought 868 Intellia Therapeutics shares in Q2 2026, an estimated $12.1K.
  • Intellia Therapeutics made up 0.01% of Kennedy Capital Management's portfolio in Q2 2026, its #521 holding.
  • Kennedy Capital Management first reported a position in Intellia Therapeutics in Q2 2021 and has held it in 12 quarters since.
  • 328 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Kennedy Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.